Logo image of RCKT

ROCKET PHARMACEUTICALS INC (RCKT) Stock Overview

NASDAQ:RCKT - US77313F1066 - Common Stock

3.24 USD
-0.04 (-1.22%)
Last: 9/2/2025, 8:00:01 PM
3.26 USD
+0.02 (+0.62%)
After Hours: 9/2/2025, 8:00:01 PM

RCKT Key Statistics, Chart & Performance

Key Statistics
52 Week High22.01
52 Week Low2.19
Market Cap349.60M
Shares107.90M
Float104.44M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.48
PEN/A
Fwd PEN/A
Earnings (Next)11-05 2025-11-05/amc
IPO02-18 2015-02-18
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


RCKT short term performance overview.The bars show the price performance of RCKT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

RCKT long term performance overview.The bars show the price performance of RCKT in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of RCKT is 3.24 USD. In the past month the price increased by 5.54%. In the past year, price decreased by -82.5%.

ROCKET PHARMACEUTICALS INC / RCKT Daily stock chart

RCKT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.01 374.37B
AMGN AMGEN INC 13.16 154.47B
GILD GILEAD SCIENCES INC 14.56 139.85B
VRTX VERTEX PHARMACEUTICALS INC 23.67 102.81B
REGN REGENERON PHARMACEUTICALS 12.66 61.25B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.59B
ARGX ARGENX SE - ADR 76.2 43.23B
ONC BEONE MEDICINES LTD-ADR 6.69 39.47B
INSM INSMED INC N/A 30.71B
BNTX BIONTECH SE-ADR N/A 24.19B
NTRA NATERA INC N/A 23.24B
BIIB BIOGEN INC 8.72 20.47B

About RCKT

Company Profile

RCKT logo image Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The company is headquartered in Cranbury, New Jersey and currently employs 299 full-time employees. The company went IPO on 2015-02-18. The firm has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.

Company Info

ROCKET PHARMACEUTICALS INC

9 Cedarbrook Drive

Cranbury NEW JERSEY 08512 US

CEO: Gaurav Shah

Employees: 299

RCKT Company Website

RCKT Investor Relations

Phone: 16464409100

ROCKET PHARMACEUTICALS INC / RCKT FAQ

What is the stock price of ROCKET PHARMACEUTICALS INC today?

The current stock price of RCKT is 3.24 USD. The price decreased by -1.22% in the last trading session.


What is the ticker symbol for ROCKET PHARMACEUTICALS INC stock?

The exchange symbol of ROCKET PHARMACEUTICALS INC is RCKT and it is listed on the Nasdaq exchange.


On which exchange is RCKT stock listed?

RCKT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ROCKET PHARMACEUTICALS INC stock?

24 analysts have analysed RCKT and the average price target is 8.08 USD. This implies a price increase of 149.43% is expected in the next year compared to the current price of 3.24. Check the ROCKET PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ROCKET PHARMACEUTICALS INC worth?

ROCKET PHARMACEUTICALS INC (RCKT) has a market capitalization of 349.60M USD. This makes RCKT a Small Cap stock.


How many employees does ROCKET PHARMACEUTICALS INC have?

ROCKET PHARMACEUTICALS INC (RCKT) currently has 299 employees.


What are the support and resistance levels for ROCKET PHARMACEUTICALS INC (RCKT) stock?

ROCKET PHARMACEUTICALS INC (RCKT) has a support level at 3 and a resistance level at 3.29. Check the full technical report for a detailed analysis of RCKT support and resistance levels.


Is ROCKET PHARMACEUTICALS INC (RCKT) expected to grow?

The Revenue of ROCKET PHARMACEUTICALS INC (RCKT) is expected to grow by 51490.9% in the next year. Check the estimates tab for more information on the RCKT EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ROCKET PHARMACEUTICALS INC (RCKT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ROCKET PHARMACEUTICALS INC (RCKT) stock pay dividends?

RCKT does not pay a dividend.


When does ROCKET PHARMACEUTICALS INC (RCKT) report earnings?

ROCKET PHARMACEUTICALS INC (RCKT) will report earnings on 2025-11-05, after the market close.


What is the Price/Earnings (PE) ratio of ROCKET PHARMACEUTICALS INC (RCKT)?

ROCKET PHARMACEUTICALS INC (RCKT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.48).


What is the Short Interest ratio of ROCKET PHARMACEUTICALS INC (RCKT) stock?

The outstanding short interest for ROCKET PHARMACEUTICALS INC (RCKT) is 11.23% of its float. Check the ownership tab for more information on the RCKT short interest.


RCKT Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to RCKT. When comparing the yearly performance of all stocks, RCKT is a bad performer in the overall market: 94.92% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

RCKT Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to RCKT. Both the profitability and financial health of RCKT have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RCKT Financial Highlights

Over the last trailing twelve months RCKT reported a non-GAAP Earnings per Share(EPS) of -2.48. The EPS increased by 11.11% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -61.05%
ROE -72.6%
Debt/Equity 0.05
Chartmill High Growth Momentum
EPS Q2Q%20.27%
Sales Q2Q%N/A
EPS 1Y (TTM)11.11%
Revenue 1Y (TTM)N/A

RCKT Forecast & Estimates

24 analysts have analysed RCKT and the average price target is 8.08 USD. This implies a price increase of 149.43% is expected in the next year compared to the current price of 3.24.

For the next year, analysts expect an EPS growth of 22.06% and a revenue growth 51490.9% for RCKT


Analysts
Analysts74.17
Price Target8.08 (149.38%)
EPS Next Y22.06%
Revenue Next Year51490.9%

RCKT Ownership

Ownership
Inst Owners90.25%
Ins Owners2.86%
Short Float %11.23%
Short Ratio2.58